INDIANAPOLIS--(BUSINESS WIRE)--Apexian Pharmaceuticals, a leading clinical-stage biotechnology company focused on developing safe and effective therapy for patients with high unmet medical needs, is pleased to announce that it will present two key poster sessions at the upcoming American Association for Cancer Research (AACR) Meeting which will be held at McCormick Place in Chicago, Illinois from April 14 – 18, 2018. Dr. Mark Kelley, Apexian’s Chief Scientific Officer, along with the research team will available at the posters session. The company will present two posters on combination therapy of APX3330 in pancreatic cancer and APE1 signaling pathway.
The titles and locations for these sessions are:
“Combination Therapy in PDAC Involving Blockade of the APE1/Ref-1 Signaling Pathway: An Investigation into Drug Synthetic Lethality and Anti-Neuropathy Therapeutic Approach”
Session Date and Time: Tuesday, April 17,
2018 from 1:00 – 5:00 PM
Location:
McCormick Place South, Exhibit Hall A, Poster Section 37
“APE1/Ref-1 Redox Signaling Regulates HIF1a-mediated CA9 Expression in Hypoxic Pancreatic Cancer Cells: Combination Treatment in Patient-derived Pancreatic Tumor Models”
Session Date and Time: Monday, April 16,
2018 from 1:00 – 5:00 PM
Location:
McCormick Place South, Exhibit Hall A, Poster Section 41
The poster sessions will add significant new information gathered on the effectiveness of Apexian’s lead clinical candidate, APX3330, and the ongoing research on the APE1/Ref-1 target.
About Apexian Pharmaceuticals
Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing safe and effective therapy for patients with high unmet medical needs. Apexian’s lead drug candidate is named APX3330. To learn more about Apexian Pharmaceuticals, please visit the company's website at www.ApexianPharma.com